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was 27 ± 10 months «1-114 months). In all pts, driving habits, ICD dis-
charges and accident occurrence were evaluated, all pts were seen in the
outpatient clinic every two months.
Results: No change in driving habits after ICD implantation was reported
by 140 pts (86%) group 1 (Gl). while the remaining 22 pts (14%) group 2 (G2)
showed modifications. During the follow-up lCD-discharges (D) occurred in
99/162 pts (61 %), in 84 pts (63%) in Gl and in 15 pts (70%) in G2. There
was a mean incidence of 18 lCD-discharges per pt in Gl and 20 ICD-D/pt in
G2. ICD-D occurred in 8 pts (5%) whilst driving a motor vehicle. 4 pts (2%)
reported on accident occurrence.
Conclusions: The incidence of ICD-D during driving is low and the major-
ity of pts do not modify their driving habits. An accident resulting from an
arrhythmic event appears to be rare and therefore, restriction of drivers' li-
censes after ICD implantation is not considered mandatory.
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Time-dependent multivariate analysis revealed ejection fraction and NYHA
class were the only variables independently related to time until death:
Conclusions: Sudden death and heart failure death occur at similar rates in
ICD pts. Ejection fraction and NYHA heart failure class are the most important
baseline determinants of time to death regardless of mechanism.
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1736-51 Quality of Life in Patients Receiving Implantable
Cardioverter Defibrillators Before Age 40
Anne M. Dubin, William P. Batsford, Richard J. Lewis, Lynda E. Rosenfeld. Yale
University. New Haven, CT
As the use of Implantable Cardioverter Defibrillators (ICD) increases, greater
numbers of young patients (pts) will receive these devices. Such pts may
have different expectations and requirements than older pts who more com-
monly receive ICDs. We investigated quality of life issues in all 25 pts fol-
lowed at Yale New Haven Hospital who were under age 40 years (13-40 y,
m = 28) at time of ICD placement. Mean time since ICD placement was 3.3
years. Four pts were excluded: 2 had devices explanted, and 2 died (1 from
sepsis and 1 from arrhythmia following ICD inactivation). Cardiac diagnoses
included: myocardial infarction m. long OT syndrome (6), cardiomyopathy
(6), and other (6).
Each pt received a modification of the New England Medical Center health
questionnaire; 16/21 responded (76%). Nine were women, and 10 were mar-
ried, 3 after ICD implantation. Highest education attained was high school
for 6 (37%), college for 7 {44%l. and graduate school for 3 (29%). Two pts
obtained graduate degrees and 4 women conceived after ICD implantation.
All delivered healthy infants including 1 whose ICD discharged during preg-
nancy. Ten pts were employed; 8 held the same job before and after ICD
placement. Two of the employed pts reported work difficulties: both reported
that they accomplished less than before, and worked less carefully.
All pts felt their health was good to excellent, with 6 reporting an improve-
ment in health since placement of the lCD, and 1 reporting a moderate de-
crease in overall health. All felt they were capable of the activities of daily
living, while 68% engaged freely in moderate physical activities. Only 31 %
felt able to fully participate in vigorous activities.
All pts felt they were average to very attractive. However, 63% worried
about how their clothes fit with the ICD and 68% worried about wearing
bathing suits (89% of the women and 43% of the men). The ICD interfered
somewhat with social interactions in 75% of pts, and 50% aVOided SOCial
functions, while 50% worried about sexual encounters, and 44% avoided
these encounters.
Thus, even though these young pts have body image concerns and limit
their activities, they are productive, active members of society, justifying ag-
gressive medical therapy and social support.
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1736-41 Time Course of Sudden Death and Heart Failure
Death in Patients with Third Generation Implantable
Cardioverter-Defibrillators
Michaela. Sweeney, Mary L. Guy, Hasan Garan, Brian McGovern, Jeremy Ruskin.
Massachusetts General Hospital, Boston, MA
Thirty seven cardiac deaths (12.2%) occurred in 301 pts with third genera-
tion implantable cardioverter-defibrillators (ICD) during a mean followup of
26 ± 15 months. There were 17 (5.6%) heart failure deaths (HFD) and 20
(6.6%) sudden cardiac deaths (SCD). Baseline variables including age, gen-
der, cardiac diagnosis, index or induced arrhythmia, and left ventricular ejec-
tion fraction were similar for HFD and SCD; mean NYHA class at ICD implant
was lower in the SCD group (p = 0.001). Kaplan-Meier survival rates for each
group were not different (Figure, p = 0.22).
1736-31 Costs and Complications of Non-thoracotomy
Defibrillator Systems: Impact of Health Care
Financing Administration Guidelines
John M. Herre, Linette R. Klevan, Martha M. Tenzer, Lauren J. Raymond, Lenox
D. Baker, Robert C. Bernstein. Eastern Virginia Medical School and Sentara Norfolk
General Hospital, Norfolk, VA
Non-thoracotomy implantable defibrillator (ICD) systems have been shown
to have lower costs and fewer complications than thoracotomy systems. Re-
cent interpretation of Health Care Financing Administration regulations has
challenged reimbursement for investigational devices or combinations of
components not approved by the Food and Drug Administration ("off-label").
We compared the costs and complications associated with approved pulse
generatorllead systems (CPI1600/Endotak, CPl1705/Endotak and Medtronic
7217!Transvene, n = 136) with investigational and "off-label" systems (CPI
1625/Endotak, CPI 1715/Endotak, Medtronic 7219!Transvene and Ventritex
Vl00 or V110/TVL and Vl00/Endotak, n = 79). Age [63 ± 12 years versus
63 ± 11 years (mean ± SD)I and ejection fraction (31 ± 15% versus 31 ±
11 %) were similar for patients with approved and investigational systems,
respectively. However, total hospital charges including preoperative care and
evaluation, implant procedure and hardware, postoperative testing and re-
visions were $64 ± 19,000 for approved devices versus $57 ± 16,000 for
non-approved devices (p = 0.02) despite higher overall costs of newer pulse
generators and leads. Total length of stay was 17 ± 10 days versus 14 ± 8
days (p = 0.03) and complications including lead dislodgement, increased
defibrillation threshold, hematoma and infection were 25/136 versus 4/77 (p
< 0.005)for approved and investigational or "off-label" systems, respectively.
Based on data provided by the manufacturers, anticipated average battery
longevity is 3.8 years for approved systems and 5.5 years for investigational
or "off-label" systems.
Conclusions: The prudent use of current investigational or "off-label" non-
thoracotomy ICD systems is more cost-effective and is associated with
fewer complications than approved ICD systems. When increased battery
longevity 'IS cons'ldered, long term costs of non-thoracotomy ICD therapy
may be improved dramatically with the use of investigational or "off-label"
systems. Review of reimbursement regulations may be warranted.
